Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Cardiovascular disease remains the world’s leading cause of death, according to a special report from the American College of Cardiology. The new analysis, described by one cardiologist as a "wake-up call," includes data from more than 200 countries and territories.

There have been so many developments in the treatment of TR that it can be challenging to keep up. The ACC crafted this new document to help ensure cardiologists, cardiac imagers and other clinicians have access to the most recent clinical data and policy decisions.

Jamieson M. Bourque, MD, MHS, previewed his plans for the future in a new interview with Cardiovascular Business. 

Approximately one in four Americans will develop heart failure in their lifetime, according to a new report from the Heart Failure Society of America. What can be done to combat this worrisome trend?

The new initiative aims to provide shock teams with objective data that can guide early management decisions and reduce mortality rates. 

Several groups collaborated on the document, which is designed to help clinicians provide high-quality, consistent care when using flurpiridaz during cardiac PET imaging exams. 

The American College of Cardiology has committed to reducing morbidity and mortality from noncommunicable diseases by 30% by 2030, but significant investments will be needed to expand the healthcare workforce.